Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Outlook TherapeuticsOTLK -10.15%14 EV-to-EBITDA is -2.35 as of Aug. 17, 2026. GuruFocus rates OTLK with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 401 Biotechnology companies, Outlook Therapeutics ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Outlook Therapeutics's enterprise value is $146.51 Mil.
Outlook Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-62.32 Mil. Therefore, Outlook Therapeutics's EV-to-EBITDA for today is -2.35.
The historical rank and industry rank for Outlook Therapeutics's EV-to-EBITDA or its related term are showing as below:
OTLK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6 Med: -1.75 Max: 0.25
Current: -2.35
During the past 12 years, the highest EV-to-EBITDA of Outlook Therapeutics was 0.25. The lowest was -6.00. And the median was -1.75.
OTLK's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs OTLK: -2.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Outlook Therapeutics (NAS:OTLK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Outlook Therapeutics's PE Ratio (TTM) for today is calculated as:
Outlook Therapeutics's share price for today is $0.6795.
Outlook Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Outlook Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Outlook Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's EV-to-EBITDA falls into.
Outlook Therapeutics's current Enterprise Value is $146.51 Mil.
Outlook Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a EV-to-EBITDA of -2.35 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Outlook Therapeutics. According to the industry distribution chart, Outlook Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry.
Is Outlook Therapeutics' EV-to-EBITDA too high?
Outlook Therapeutics' current EV-to-EBITDA is -2.35. Based on the distribution chart, Outlook Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' EV-to-EBITDA compare to SLGL and SABS?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #999999 out of 401 companies for EV-to-EBITDA. This places Outlook Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Outlook Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current EV-to-EBITDA is -2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current EV-to-EBITDA of -2.35. The current EV-to-EBITDA is -2.35. Outlook Therapeutics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current EV-to-EBITDA is -2.35 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
14GF Score
Get the complete analysis for OTLK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
